{"transactions":[{"id":814731,"issuer":{"id":8097,"kind":"organization","name":"20/20 Biolabs, Inc."},"owners":[{"id":53650,"kind":"person","name":"Bergman Alan B.","position":1,"cik":"0001907908","reported_name":"Bergman Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2026-04-06T21:56:49.000Z","date":"2026-04-02","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"25,000 of the shares subject to the stock option will vest on the first anniversary of the date of grant and the remaining shares will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service to the Issuer."},{"field":"kind","element":"transactionCoding","label":"F1","text":"25,000 of the shares subject to the stock option will vest on the first anniversary of the date of grant and the remaining shares will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25,000 of the shares subject to the stock option will vest on the first anniversary of the date of grant and the remaining shares will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":100000,"derivative":{"exercise_price":1.88,"expiration_date":"2036-04-02","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-26-040583","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026040583/ownership.xml","form_type":"4"}},{"id":814730,"issuer":{"id":8097,"kind":"organization","name":"20/20 Biolabs, Inc."},"owners":[{"id":53649,"kind":"person","name":"Zhou Jiming","position":1,"cik":"0002109760","reported_name":"Zhou Jiming","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option","published_at":"2026-04-06T21:56:27.000Z","date":"2026-04-02","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":150000,"derivative":{"exercise_price":1.88,"exercise_date":"2026-04-02","expiration_date":"2036-04-02","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001213900-26-040581","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026040581/ownership.xml","form_type":"4"}},{"id":862591,"issuer":{"id":8097,"kind":"organization","name":"20/20 Biolabs, Inc."},"owners":[{"id":62917,"kind":"person","name":"Cohen Jonathan M","position":1,"cik":"0002111543","reported_name":"Cohen Jonathan M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2026-03-04T22:48:56.000Z","date":"2026-03-03","kind":"grant","planned":false,"acquired":true,"shares":352936,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On March 3, 2026, the Reporting Person was granted a stock option for the purchase of 352,936 shares of common stock, which shall vest in equal quarterly installments over the following four (4) years, subject to the Reporting Person's continuous service to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 3, 2026, the Reporting Person was granted a stock option for the purchase of 352,936 shares of common stock, which shall vest in equal quarterly installments over the following four (4) years, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":352936,"derivative":{"exercise_price":3.39,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":352936},"source":{"system":"sec-edgar","filing":"0001213900-26-023758","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026023758/ownership.xml","form_type":"4"}},{"id":888502,"issuer":{"id":8097,"kind":"organization","name":"20/20 Biolabs, Inc."},"owners":[{"id":65219,"kind":"person","name":"Rollins John Woodson","position":1,"cik":"0002112941","reported_name":"Rollins John Woodson","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2026-02-24T00:09:32.000Z","date":"2026-02-19","kind":"exercise","planned":false,"acquired":false,"shares":6135,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6135},"source":{"system":"sec-edgar","filing":"0001213900-26-019456","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026019456/ownership.xml","form_type":"4"}},{"id":888501,"issuer":{"id":8097,"kind":"organization","name":"20/20 Biolabs, Inc."},"owners":[{"id":65219,"kind":"person","name":"Rollins John Woodson","position":1,"cik":"0002112941","reported_name":"Rollins John Woodson","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-02-24T00:09:32.000Z","date":"2026-02-19","kind":"exercise","planned":false,"acquired":false,"shares":13029,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13029},"source":{"system":"sec-edgar","filing":"0001213900-26-019456","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026019456/ownership.xml","form_type":"4"}},{"id":888500,"issuer":{"id":8097,"kind":"organization","name":"20/20 Biolabs, Inc."},"owners":[{"id":65219,"kind":"person","name":"Rollins John Woodson","position":1,"cik":"0002112941","reported_name":"Rollins John Woodson","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-24T00:09:32.000Z","date":"2026-02-19","kind":"exercise","planned":false,"acquired":true,"shares":6135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."}],"balance_after":30275,"source":{"system":"sec-edgar","filing":"0001213900-26-019456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026019456/ownership.xml","form_type":"4"}},{"id":888499,"issuer":{"id":8097,"kind":"organization","name":"20/20 Biolabs, Inc."},"owners":[{"id":65219,"kind":"person","name":"Rollins John Woodson","position":1,"cik":"0002112941","reported_name":"Rollins John Woodson","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-24T00:09:32.000Z","date":"2026-02-19","kind":"exercise","planned":false,"acquired":true,"shares":13029,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date."}],"balance_after":24140,"source":{"system":"sec-edgar","filing":"0001213900-26-019456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026019456/ownership.xml","form_type":"4"}},{"id":888498,"issuer":{"id":8097,"kind":"organization","name":"20/20 Biolabs, Inc."},"owners":[{"id":65220,"kind":"person","name":"Ross Michael A.","position":1,"cik":"0002109744","reported_name":"Ross Michael A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2026-02-23T23:13:34.000Z","date":"2026-02-19","kind":"exercise","planned":false,"acquired":false,"shares":31,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":31},"source":{"system":"sec-edgar","filing":"0001213900-26-019424","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026019424/ownership.xml","form_type":"4"}},{"id":888497,"issuer":{"id":8097,"kind":"organization","name":"20/20 Biolabs, Inc."},"owners":[{"id":65220,"kind":"person","name":"Ross Michael A.","position":1,"cik":"0002109744","reported_name":"Ross Michael A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T23:13:34.000Z","date":"2026-02-19","kind":"exercise","planned":false,"acquired":true,"shares":31,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."}],"balance_after":31,"source":{"system":"sec-edgar","filing":"0001213900-26-019424","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026019424/ownership.xml","form_type":"4"}},{"id":888496,"issuer":{"id":8097,"kind":"organization","name":"20/20 Biolabs, Inc."},"owners":[{"id":65218,"kind":"person","name":"Compton John G.","position":1,"cik":"0002107487","reported_name":"Compton John G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2026-02-23T23:13:20.000Z","date":"2026-02-19","kind":"exercise","planned":false,"acquired":false,"shares":7669,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7669},"source":{"system":"sec-edgar","filing":"0001213900-26-019423","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026019423/ownership.xml","form_type":"4"}},{"id":888495,"issuer":{"id":8097,"kind":"organization","name":"20/20 Biolabs, Inc."},"owners":[{"id":65218,"kind":"person","name":"Compton John G.","position":1,"cik":"0002107487","reported_name":"Compton John G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T23:13:20.000Z","date":"2026-02-19","kind":"exercise","planned":false,"acquired":true,"shares":7669,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."}],"balance_after":14335,"source":{"system":"sec-edgar","filing":"0001213900-26-019423","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026019423/ownership.xml","form_type":"4"}},{"id":888879,"issuer":{"id":8097,"kind":"organization","name":"20/20 Biolabs, Inc."},"owners":[{"id":21359,"kind":"person","name":"COHEN RICHARD M","position":1,"cik":"0001075891","reported_name":"COHEN RICHARD M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2026-02-23T23:13:03.000Z","date":"2026-02-19","kind":"exercise","planned":false,"acquired":false,"shares":7700,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7700},"source":{"system":"sec-edgar","filing":"0001213900-26-019421","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1075891/000121390026019421/ownership.xml","form_type":"4"}},{"id":888878,"issuer":{"id":8097,"kind":"organization","name":"20/20 Biolabs, Inc."},"owners":[{"id":21359,"kind":"person","name":"COHEN RICHARD M","position":1,"cik":"0001075891","reported_name":"COHEN RICHARD M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-23T23:13:03.000Z","date":"2026-02-19","kind":"exercise","planned":false,"acquired":true,"shares":7700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."}],"balance_after":7700,"source":{"system":"sec-edgar","filing":"0001213900-26-019421","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1075891/000121390026019421/ownership.xml","form_type":"4"}}]}